{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:28:49Z","timestamp":1792535329087,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T00:00:00Z","timestamp":1408406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/nrrheum.2014.124","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T12:53:18Z","timestamp":1408452798000},"page":"654-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":187,"title":["Improving cardiovascular and renal outcomes in gout: what should we target?"],"prefix":"10.1038","volume":"10","author":[{"given":"Pascal","family":"Richette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliseo","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,19]]},"reference":[{"key":"BFnrrheum2014124_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig, D. I., Kang, D. H. & Johnson, R. J. Uric acid and cardiovascular risk. N. Engl. J. Med. 359, 1811\u20131821 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2014124_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette, P. & Bardin, T. Gout. Lancet 375, 318\u2013328 (2010).","journal-title":"Lancet"},{"key":"BFnrrheum2014124_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","volume":"26","author":"T Bardin","year":"2014","unstructured":"Bardin, T. & Richette, P. Definition of hyperuricemia and gouty conditions. Curr. Opin. Rheumatol. 26, 186\u2013191 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014124_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/rheumatology\/kes223","volume":"52","author":"CF Kuo","year":"2013","unstructured":"Kuo, C. F. et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 52, 127\u2013134 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014124_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","volume":"41","author":"RD Abbott","year":"1988","unstructured":"Abbott, R. D., Brand, F. N., Kannel, W. B. & Castelli, W. P. Gout and coronary heart disease: the Framingham Study. J. Clin. Epidemiol. 41, 237\u2013242 (1988).","journal-title":"J. Clin. Epidemiol."},{"key":"BFnrrheum2014124_CR6","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan, E., Baker, J. F., Furst, D. E. & Schumacher, H. R. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 54, 2688\u20132696 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014124_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi, H. K. & Curhan, G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116, 894\u2013900 (2007).","journal-title":"Circulation"},{"key":"BFnrrheum2014124_CR8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2009.122770","volume":"69","author":"MA De Vera","year":"2010","unstructured":"De Vera, M. A., Rahman, M. M., Bhole, V., Kopec, J. A. & Choi, H. K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann. Rheum. Dis. 69, 1162\u20131164 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0003319707303444","volume":"58","author":"JF Baker","year":"2007","unstructured":"Baker, J. F., Schumacher, H. R. & Krishnan, E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 58, 450\u2013457 (2007).","journal-title":"Angiology"},{"key":"BFnrrheum2014124_CR10","doi-asserted-by":"publisher","first-page":"e000282","DOI":"10.1136\/bmjopen-2011-000282","volume":"15","author":"E Krishnan","year":"2012","unstructured":"Krishnan, E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 15, e000282 (2012).","journal-title":"BMJ Open"},{"key":"BFnrrheum2014124_CR11","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/rheumatology\/ket293","volume":"52","author":"OO Seminog","year":"2013","unstructured":"Seminog, O. O. & Goldacre, M. J. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford) 52, 2251\u20132259 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014124_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11926-011-0234-2","volume":"14","author":"K Lottmann","year":"2012","unstructured":"Lottmann, K., Chen, X. & Schadlich, P. K. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr. Rheumatol. Rep. 14, 195\u2013203 (2012).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum2014124_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/qjmed\/hct083","volume":"106","author":"AG Stack","year":"2013","unstructured":"Stack, A. G. et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106, 647\u2013658 (2013).","journal-title":"QJM"},{"key":"BFnrrheum2014124_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/ard.2011.200523","volume":"71","author":"GG Teng","year":"2012","unstructured":"Teng, G. G. et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann. Rheum. Dis. 71, 924\u2013928 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz, F. et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann. Rheum. Dis. 73, 177\u2013182 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","volume":"62","author":"SY Kim","year":"2010","unstructured":"Kim, S. Y. et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 62, 170\u2013180 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014124_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s10067-006-0292-4","volume":"26","author":"SY Chen","year":"2007","unstructured":"Chen, S. Y., Chen, C. L. & Shen, M. L. Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. Clin. Rheumatol. 26, 308\u2013313 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum2014124_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","volume":"131","author":"BF Culleton","year":"1999","unstructured":"Culleton, B. F., Larson, M. G., Kannel, W. B. & Levy, D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 131, 7\u201313 (1999).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2014124_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/art.24612","volume":"61","author":"SY Kim","year":"2009","unstructured":"Kim, S. Y. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 61, 885\u2013892 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014124_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/acr.20344","volume":"63","author":"PC Grayson","year":"2010","unstructured":"Grayson, P. C., Kim, S. Y., LaValley, M. & Choi, H. K. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 63, 102\u2013110 (2010).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum2014124_CR21","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1373\/clinchem.2009.124891","volume":"55","author":"W Zhang","year":"2009","unstructured":"Zhang, W. et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin. Chem. 55, 2026\u20132034 (2009).","journal-title":"Clin. Chem."},{"key":"BFnrrheum2014124_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/annrheumdis-2012-201916","volume":"72","author":"AL Gaffo","year":"2013","unstructured":"Gaffo, A. L. et al. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann. Rheum. Dis. 72, 1321\u20131327 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.183244","volume":"59","author":"LF Loeffler","year":"2012","unstructured":"Loeffler, L. F., Navas-Acien, A., Brady, T. M., Miller, E. R. 3rd & Fadrowski, J. J. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999\u20132006. Hypertension 59, 811\u2013817 (2012).","journal-title":"Hypertension"},{"key":"BFnrrheum2014124_CR24","doi-asserted-by":"publisher","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali, M. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal Physiol. 282, F991\u2013F997 (2002).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrrheum2014124_CR25","doi-asserted-by":"publisher","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","volume":"283","author":"LG Sanchez-Lozada","year":"2002","unstructured":"Sanchez-Lozada, L. G. et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am. J. Physiol. Renal Physiol. 283, F1105\u2013F1110 (2002).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrrheum2014124_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi, H. K., Ford, E. S., Li, C. & Curhan, G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 57, 109\u2013115 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014124_CR27","doi-asserted-by":"publisher","first-page":"e56864","DOI":"10.1371\/journal.pone.0056864","volume":"8","author":"Q Lv","year":"2013","unstructured":"Lv, Q. et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE 8, e56864 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2014124_CR28","first-page":"E1","volume":"268","author":"A Quinones Galvan","year":"1995","unstructured":"Quinones Galvan, A. et al. Effect of insulin on uric acid excretion in humans. Am. J. Physiol. 268, E1\u2013E5 (1995).","journal-title":"Am. J. Physiol."},{"key":"BFnrrheum2014124_CR29","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2337\/dc09-0288","volume":"32","author":"S Kodama","year":"2009","unstructured":"Kodama, S. et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 32, 1737\u20131742 (2009).","journal-title":"Diabetes Care"},{"key":"BFnrrheum2014124_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2337\/dc10-0918","volume":"34","author":"F Viazzi","year":"2011","unstructured":"Viazzi, F., Leoncini, G., Vercelli, M., Deferrari, G. & Pontremoli, R. Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. Diabetes Care 34, 126\u2013128 (2011).","journal-title":"Diabetes Care"},{"key":"BFnrrheum2014124_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.amjmed.2010.03.027","volume":"123","author":"V Bhole","year":"2010","unstructured":"Bhole, V., Choi, J. W., Kim, S. W, de Vera, M. & Choi, H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am. J. Med. 123, 957\u2013961 (2010).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2014124_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.amjhyper.2006.02.014","volume":"19","author":"A Onat","year":"2006","unstructured":"Onat, A. et al. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am. J. Hypertens. 19, 1055\u20131062 (2006).","journal-title":"Am. J. Hypertens."},{"key":"BFnrrheum2014124_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jpeds.2012.03.036","volume":"161","author":"JY Wang","year":"2012","unstructured":"Wang, J. Y. et al. Predictive value of serum uric acid levels for the diagnosis of metabolic syndrome in adolescents. J. Pediatr. 161, 753\u2013756.e2 (2012).","journal-title":"J. Pediatr."},{"key":"BFnrrheum2014124_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/MNH.0b013e328305b9a5","volume":"17","author":"S Reungjui","year":"2008","unstructured":"Reungjui, S., Pratipanawatr, T., Johnson, R. & Nakagawa, T. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr. Opin. Nephrol. Hypertens. 17, 470\u2013476 (2008).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrrheum2014124_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1743-7075-9-68","volume":"9","author":"CL Cox","year":"2012","unstructured":"Cox, C. L. et al. Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight\/obese humans. Nutr. Metab. (Lond.) 9, 68 (2012).","journal-title":"Nutr. Metab. (Lond.)"},{"key":"BFnrrheum2014124_CR36","doi-asserted-by":"publisher","first-page":"F423","DOI":"10.1152\/ajprenal.00124.2006","volume":"292","author":"LG Sanchez-Lozada","year":"2007","unstructured":"Sanchez-Lozada, L. G. et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am. J. Physiol. Renal Physiol. 292, F423\u2013F429 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrrheum2014124_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ijo.2009.259","volume":"34","author":"SE Perez-Pozo","year":"2010","unstructured":"Perez-Pozo, S. E. et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int. J. Obes. (Lond.) 34, 454\u2013461 (2010).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"BFnrrheum2014124_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","volume":"336","author":"HK Choi","year":"2008","unstructured":"Choi, H. K. & Curhan, G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336, 309\u2013312 (2008).","journal-title":"BMJ"},{"key":"BFnrrheum2014124_CR39","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1001\/jama.2010.1638","volume":"304","author":"HK Choi","year":"2010","unstructured":"Choi, H. K., Willett, W. & Curhan, G. Fructose-rich beverages and risk of gout in women. JAMA 304, 2270\u20132278 (2010).","journal-title":"JAMA"},{"key":"BFnrrheum2014124_CR40","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI42344","volume":"120","author":"A So","year":"2010","unstructured":"So, A. & Thorens, B. Uric acid transport and disease. J. Clin. Invest. 120, 1791\u20131799 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2014124_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2011","unstructured":"Zhu, Y., Pandya, B. J. & Choi, H. K. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am. J. Med. 125, 679\u2013687.e1 (2011).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2014124_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2012.07.021","volume":"61","author":"DI Jalal","year":"2013","unstructured":"Jalal, D. I., Chonchol, M., Chen, W. & Targher, G. Uric acid as a target of therapy in CKD. Am. J. Kidney Dis. 61, 134\u2013146 (2013).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrrheum2014124_CR43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson, R. J. et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol. Dial. Transplant. 28, 2221\u20132228 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrrheum2014124_CR44","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/ndt\/gfg140","volume":"18","author":"T Umekawa","year":"2003","unstructured":"Umekawa, T., Chegini, N. & Khan, S. R. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol. Dial. Transplant. 18, 664\u2013669 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrrheum2014124_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10157-012-0609-3","volume":"16","author":"H Omori","year":"2012","unstructured":"Omori, H. et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin. Exp. Nephrol. 16, 549\u2013556 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrrheum2014124_CR46","doi-asserted-by":"publisher","first-page":"F710","DOI":"10.1152\/ajprenal.00454.2007","volume":"294","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada, L. G. et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 294, F710\u2013F718 (2008).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrrheum2014124_CR47","doi-asserted-by":"publisher","first-page":"F481","DOI":"10.1152\/ajprenal.00092.2009","volume":"297","author":"T Kosugi","year":"2009","unstructured":"Kosugi, T. et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db\/db mice. Am. J. Physiol. Renal Physiol. 297, F481\u2013F488 (2009).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrrheum2014124_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/art.1780340203","volume":"34","author":"E Pascual","year":"1991","unstructured":"Pascual, E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 34, 141\u2013145 (1991).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 2","key":"BFnrrheum2014124_CR49","first-page":"ii9","volume":"48","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz, F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 48 (Suppl. 2), ii9\u2013ii14 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014124_CR50","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.27356","volume":"62","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth, N. et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum. 62, 1549\u20131556 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2014124_CR51","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71, 1839\u20131848 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR52","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/annrheumdis-2012-202301","volume":"72","author":"PV Chowalloor","year":"2013","unstructured":"Chowalloor, P. V. & Keen, H. I. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann. Rheum. Dis. 72, 638\u2013645 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR53","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/ar3223","volume":"13","author":"C Pineda","year":"2011","unstructured":"Pineda, C. et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res. Ther. 13, R4 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2014124_CR54","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/15257770802136040","volume":"27","author":"JG Puig","year":"2008","unstructured":"Puig, J. G. et al. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 27, 592\u2013595 (2008).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"BFnrrheum2014124_CR55","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.2174\/138161205774913309","volume":"11","author":"SS Daskalopoulou","year":"2005","unstructured":"Daskalopoulou, S. S., Tzovaras, V., Mikhailidis, D. P. & Elisaf, M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr. Pharm. Des. 11, 4161\u20134175 (2005).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrrheum2014124_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CRD.0b013e318229a908","volume":"19","author":"A Kelkar","year":"2011","unstructured":"Kelkar, A., Kuo, A. & Frishman, W. H. Allopurinol as a cardiovascular drug. Cardiol. Rev. 19, 265\u2013271 (2011).","journal-title":"Cardiol. Rev."},{"key":"BFnrrheum2014124_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11910-012-0282-7","volume":"12","author":"X Chen","year":"2012","unstructured":"Chen, X., Wu, G. & Schwarzschild, M. A. Urate in Parkinson's disease: more than a biomarker? Curr. Neurol. Neurosci. Rep. 12, 367\u2013375 (2012).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrrheum2014124_CR58","doi-asserted-by":"publisher","first-page":"14351","DOI":"10.1073\/pnas.1001072107","volume":"107","author":"MS Hershfield","year":"2010","unstructured":"Hershfield, M. S. et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc. Natl Acad. Sci. USA 107, 14351\u201314356 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2014124_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher, P., Nivorozhkin, A. & Szabo, C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 58, 87\u2013114 (2006).","journal-title":"Pharmacol. Rev."},{"key":"BFnrrheum2014124_CR60","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1592\/phco.30.6.594","volume":"30","author":"BL Love","year":"2010","unstructured":"Love, B. L., Barrons, R., Veverka, A. & Snider, K. M. Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 30, 594\u2013608 (2010).","journal-title":"Pharmacotherapy"},{"key":"BFnrrheum2014124_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2011.04.004","volume":"51","author":"UZ Malik","year":"2011","unstructured":"Malik, U. Z. et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic. Biol. Med. 51, 179\u2013184 (2011).","journal-title":"Free Radic. Biol. Med."},{"key":"BFnrrheum2014124_CR62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"S Kaptoge","year":"2010","unstructured":"Kaptoge, S. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132\u2013140 (2010).","journal-title":"Lancet"},{"key":"BFnrrheum2014124_CR63","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"BFnrrheum2014124_CR64","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"BFnrrheum2014124_CR65","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/rheumatology\/ket001","volume":"52","author":"S Inaba","year":"2013","unstructured":"Inaba, S., Sautin, Y., Garcia, G. E. & Johnson, R. J. What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us? Rheumatology (Oxford) 52, 963\u2013965 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2014124_CR66","doi-asserted-by":"publisher","first-page":"e45907","DOI":"10.1371\/journal.pone.0045907","volume":"7","author":"D Rothenbacher","year":"2012","unstructured":"Rothenbacher, D. et al. Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease. PLoS ONE 7, e45907 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2014124_CR67","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1161\/01.HYP.0000072820.07472.3B","volume":"41","author":"J Kanellis","year":"2003","unstructured":"Kanellis, J. et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41, 1287\u20131293 (2003).","journal-title":"Hypertension"},{"key":"BFnrrheum2014124_CR68","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature01991","volume":"425","author":"Y Shi","year":"2003","unstructured":"Shi, Y., Evans, J. E. & Rock, K. L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516\u2013521 (2003).","journal-title":"Nature"},{"key":"BFnrrheum2014124_CR69","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633\u2013652 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrrheum2014124_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","volume":"30","author":"P Higgins","year":"2012","unstructured":"Higgins, P. et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 30, 217\u2013226 (2012).","journal-title":"Cardiovasc. Ther."},{"key":"BFnrrheum2014124_CR71","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jacc.2010.12.052","volume":"58","author":"NS Rajendra","year":"2011","unstructured":"Rajendra, N. S. et al. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J. Am. Coll. Cardiol. 58, 820\u2013828 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrrheum2014124_CR72","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman, A., Ang, D. S., Ogston, S., Lang, C. C. & Struthers, A. D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375, 2161\u20132167 (2010).","journal-title":"Lancet"},{"key":"BFnrrheum2014124_CR73","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/archinternmed.2010.198","volume":"170","author":"G Thanassoulis","year":"2010","unstructured":"Thanassoulis, G., Brophy, J. M., Richard, H. & Pilote, L. Gout, allopurinol use, and heart failure outcomes. Arch. Intern. Med. 170, 1358\u20131364 (2010).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum2014124_CR74","doi-asserted-by":"publisher","unstructured":"Grimaldi-Bensouda, L. et al. Impact of allopurinol on risk of myocardial infarction. Ann. Rheum. Dis. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2012-202972 (2014).","DOI":"10.1136\/annrheumdis-2012-202972"},{"key":"BFnrrheum2014124_CR75","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","volume":"43","author":"VG Athyros","year":"2004","unstructured":"Athyros, V. G. et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis. 43, 589\u2013599 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrrheum2014124_CR76","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1523-1755.2004.00484.x","volume":"65","author":"A Hoieggen","year":"2004","unstructured":"Hoieggen, A. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 65, 1041\u20131049 (2004).","journal-title":"Kidney Int."},{"key":"BFnrrheum2014124_CR77","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George, J., Carr, E., Davies, J., Belch, J. J. & Struthers, A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114, 2508\u20132516 (2006).","journal-title":"Circulation"},{"key":"BFnrrheum2014124_CR78","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","volume":"3","author":"K Ogino","year":"2010","unstructured":"Ogino, K. et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ. Heart Fail. 3, 73\u201381 (2010).","journal-title":"Circ. Heart Fail."},{"key":"BFnrrheum2014124_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1751-7133.2011.00262.x","volume":"18","author":"A Harzand","year":"2012","unstructured":"Harzand, A., Tamariz, L. & Hare, J. M. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest. Heart Fail. 18, 179\u2013182 (2012).","journal-title":"Congest. Heart Fail."},{"key":"BFnrrheum2014124_CR80","doi-asserted-by":"publisher","unstructured":"Gois, P. H. & Souza, E. R. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD008652. http:\/\/dx.doi.org\/10.1002\/14651858.CD008652.pub2 .","DOI":"10.1002\/14651858.CD008652.pub2"},{"key":"BFnrrheum2014124_CR81","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1751-7176.2012.00701.x","volume":"15","author":"V Agarwal","year":"2013","unstructured":"Agarwal, V., Hans, N. & Messerli, F. H. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J. Clin. Hypertens. (Greenwich) 15, 435\u2013442 (2013).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"BFnrrheum2014124_CR82","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"DI Feig","year":"2008","unstructured":"Feig, D. I., Soletsky, B. & Johnson, R. J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924\u2013932 (2008).","journal-title":"JAMA"},{"key":"BFnrrheum2014124_CR83","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","volume":"60","author":"B Soletsky","year":"2012","unstructured":"Soletsky, B. & Feig, D. I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 60, 1148\u20131156 (2012).","journal-title":"Hypertension"},{"key":"BFnrrheum2014124_CR84","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","volume":"77","author":"A Sezai","year":"2013","unstructured":"Sezai, A. et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ. J. 77, 2043\u20132049 (2013).","journal-title":"Circ. J."},{"key":"BFnrrheum2014124_CR85","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3109\/08037051.2010.532323","volume":"20","author":"K Kostka-Jeziorny","year":"2011","unstructured":"Kostka-Jeziorny, K., Uruski, P. & Tykarski, A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press. 20, 104\u2013110 (2011).","journal-title":"Blood Press."},{"key":"BFnrrheum2014124_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu, Y. P., Leung, K. T., Tong, M. K. & Kwan, T. H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47, 51\u201359 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrrheum2014124_CR87","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5, 1388\u20131393 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrrheum2014124_CR88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","volume":"58","author":"Y Miao","year":"2011","unstructured":"Miao, Y. et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58, 2\u20137 (2011).","journal-title":"Hypertension"},{"key":"BFnrrheum2014124_CR89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton, A., Macdonald, P. A., Zhao, L., Hunt, B. & Gunawardhana, L. Renal function in gout: long-term treatment effects of febuxostat. J. Clin. Rheumatol. 17, 7\u201313 (2011).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrrheum2014124_CR90","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/BOR.0b013e32835cedd4","volume":"25","author":"TJ Gibson","year":"2013","unstructured":"Gibson, T. J. Hypertension, its treatment, hyperuricaemia and gout. Curr. Opin. Rheumatol. 25, 217\u2013222 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2014124_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/ard.41.1.59","volume":"41","author":"T Gibson","year":"1982","unstructured":"Gibson, T., Rodgers, V., Potter, C. & Simmonds, H. A. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann. Rheum. Dis. 41, 59\u201365 (1982).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2014124_CR92","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404\u2013410 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrrheum2014124_CR93","first-page":"600","volume":"19","author":"E Pascual","year":"1992","unstructured":"Pascual, E. & Castellano, J. A. Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J. Rheumatol. 19, 600\u2013603 (1992).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014124_CR94","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.111533","volume":"39","author":"DB Crittenden","year":"2012","unstructured":"Crittenden, D. B. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 39, 1458\u20131464 (2012).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2014124_CR95","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","volume":"99","author":"M Nidorf","year":"2007","unstructured":"Nidorf, M. & Thompson, P. L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am. J. Cardiol. 99, 805\u2013807 (2007).","journal-title":"Am. J. Cardiol."},{"key":"BFnrrheum2014124_CR96","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","volume":"33","author":"NC Raju","year":"2012","unstructured":"Raju, N. C. et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J. Thromb. Thrombolysis 33, 88\u201394 (2012).","journal-title":"J. Thromb. Thrombolysis"},{"key":"BFnrrheum2014124_CR97","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1161\/STROKEAHA.108.519793","volume":"39","author":"SW Muir","year":"2008","unstructured":"Muir, S. W. et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 39, 3303\u20133307 (2008).","journal-title":"Stroke"},{"key":"BFnrrheum2014124_CR98","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11255-007-9253-3","volume":"39","author":"M Kanbay","year":"2007","unstructured":"Kanbay, M. et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int. Urol. Nephrol. 39, 1227\u20131233 (2007).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrrheum2014124_CR99","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00392-007-0636-3","volume":"97","author":"O Yiginer","year":"2008","unstructured":"Yiginer, O. et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin. Res. Cardiol. 97, 334\u2013340 (2008).","journal-title":"Clin. Res. Cardiol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.124","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2014.124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T16:59:54Z","timestamp":1717261194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2014.124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,19]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["BFnrrheum2014124"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2014.124","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,19]]},"assertion":[{"value":"19 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have received consultancy and\/or speaker fees from Abbott (T.L.J.), Ardea Biosciences (F.P.-R., M.D., G.N., A.K.S., T.B.), Astra Zeneca (P.R.), Biocryst (G.N., T.B.), Ipsen (P.R., M.D., T.L.J., G.N., A.K.S., T.B.), Menarini (P.R., F.P.-R., M.D., T.L.J., G.N., E.P., A.K.S., T.B.), Metabolex (F.P.-R.), Novartis (P.R., F.P.-R., M.D., G.N., A.K.S., T.B.), Pfizer (F.P.-R.), Roche (T.L.J.), Sanofi (P.R.), Savient (P.R., F.P.-R. G.N., M.D., E.P., T.B.) and UCB (T.L.J.). F.P.-R. declares he has received grants from Ministerio de Sanidad, Gobierno de Espa\u00f1a and Asociaci\u00f3n de Reumat\u00f3logos del Hospital de Cruces. P.R. declares he has received an educational grant from Menarini.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}